FHDH-ANRS CO4 Cohort: HCV Incidence in MSM With HIV Declined Following Access to HCV DAA Therapy in France

March 8-11, 2020; Boston, Massachusetts
HCV incidence in MSM with HIV in France declined from 2014 to 2017 following unrestricted access of HCV DAA therapy for persons with HIV.
Format: Microsoft PowerPoint (.ppt)
File Size: 156 KB
Released: March 17, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients who are coinfected with HBV/HIV and TB/HIV.

person default Daria Podlekareva, MD, PhD Mark S. Sulkowski, MD Released: December 29, 2021

Clinical Care Options (CCO) presents a woman’s perspective on her journey from a late HIV diagnosis to treatment, suppression, and searching for her purpose

person default Anonymous Patient Released: December 27, 2021

Expert commentary on initial ART in patients with HIV and opportunistic infections, from Dr Cristina Mussini and Clinical Care Options (CCO)

Cristina Mussini, MD Released: December 13, 2021

Dr Milosz Parczewski and Clinical Care Options (CCO): Update from EACS 2021 on the HIV care continuum in Eastern Europe

Milosz Parczewski, MD, PhD Released: December 3, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings